Abstract
The quadrivalent prophylactic HPV vaccination against HPV types 6, 11, 16 and 18 is not only highly effective in preventing HPV 16 and 18-associated cervical cancer, precancerous cervical lesions and high-grade precancerous vulvar and vaginal lesions but also against HPV 6 and 11-associated genital warts. Therefore, HPV-vaccination clearly belongs to the dermatologists' field of responsibility. A survey among 770 German dermatologists showed broad acceptance of the HPV vaccination; two-thirds of the persons asked would recommend the vaccination to their patients, regardless of reimbursement or STIKO recommendation, if they are convinced of the medical benefit. The survey also showed that HPV vaccination has not yet been fully established among dermatologists. Taking the high efficacy of the quadrivalent HPV vaccine into account, dermatologists should actively offer the HPV vaccination to their patients. The current AWMF-S3-guideline "Impfprävention HPV-assoziierter Neoplasien"can be used as a decision-making basis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
